StreetInsider.com News Articles

Coherus BioSciences (CHRS) Tops Q2 EPS by 7c

Wed, 05 Aug 2026 17:49:06 -0400

Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $14.31 million versus the consensus estimate of $14.41 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

Form S-8 Coherus Oncology, Inc.

Wed, 05 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26876046.html

Form S-8 Coherus Oncology, Inc.

Wed, 05 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26876046.html

Form 10-Q Coherus Oncology, Inc. For: Jun 30

Wed, 05 Aug 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260805/26875896.html

Form 10-Q Coherus Oncology, Inc. For: Jun 30

Wed, 05 Aug 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260805/26875896.html

Form 8-K Coherus Oncology, Inc. For: Aug 05

Wed, 05 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260805/26875307.html

Form 8-K Coherus Oncology, Inc. For: Aug 05

Wed, 05 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260805/26875307.html

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter 2026, and provided an overview of recent business

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:28:00 -0400

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –

– Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer –

– Projected October public disclosure of data sets with sufficient maturity –

– Conference call today at 5:00 p.m. Eastern Daylight Time –

Form SCHEDULE 13G Coherus Oncology, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819950.html

Form SCHEDULE 13G Coherus Oncology, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819950.html

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 13:36:00 -0400

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 13:36:00 -0400

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 13:36:00 -0400

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 13:36:00 -0400

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight

Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi

Tue, 23 Jun 2026 14:09:02 -0400

Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. announced a clinical collaboration and supply agreement to conduct a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi), according to a press release.

The trial (NCT06451497) will enroll up to 45 patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma, urothelial cancers, and other solid tumors across dose-escalation and expansion cohorts in the United States. The study will assess safety, tolerability, and the recommended dose of ZM008.

Under the agreement, Coherus Oncology will supply LOQTORZI to Zumutor, which

Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi

Tue, 23 Jun 2026 14:09:02 -0400

Under the agreement, Coherus Oncology will supply LOQTORZI to Zumutor, which

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Tue, 23 Jun 2026 14:00:00 -0400

REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.

“We are excited to partner with Zumutor Biologics on the development

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Tue, 23 Jun 2026 14:00:00 -0400

“We are excited to partner with Zumutor Biologics on the development